Data from the Amazona study found that almost 70% of patients are diagnosed with estrogen receptor (ER)/progesterone receptor (PR) positive BC, around 20% with HER-2 positive (ER/PR positive or negative) and 21% with triple-negative subtype [15]. This evidence concerns the gene ESR1 and breast cancer.